Hospital-Acquired Disease Testing Market: Overview, Industry Top Manufactures, Market Size, Opportunities and Forecast

According to the latest report by IMARC Group, the global hospital acquired disease testing market size reached US$ 876 Million in 2018. A hospital-acquired infection (HAI), also known as a nosocomial infection, is acquired from hospitals or clinical surroundings such as nursing homes and rehabilitation centers. In several cases, HAI can also be traced in the patient’s microbiome when the protective layer of skin comes in contact with possible threats, which cause infection, particularly after surgical operations. The incubation period of these diseases generally varies from 48 hours to 4 days. Some of the commonly occurring infections include pneumonia, urinary tract infections (UTI) and primary bloodstream infections.

Market Trends:

Most patients develop HAIs when they are admitted in emergency rooms (ERs) or intensive care units (ICUs) due to the presence of infected patients as well as contaminated linens, air droplets and hospital equipment. In recent years, owing to rapid urbanization, increasing global population, and modernization of healthcare infrastructure, the number of healthcare facilities has grown around the world, which has consequently led to a rise in the instances of HAIs. Moreover, with continuous innovation in the healthcare sector, various technologies have been developed to prevent, diagnose and monitor HAIs like microarrays, solid phase hybridization, polymerase chain reaction (PCR) and real-time location systems (RTLSs). Some of the other growth-inducing factors are inflating morbidity rates, increasing geriatric population, lack of proper hygiene in hospitals and rise in multi-drug resistant organisms (MDROs). Looking forward, the market is projected to reach a value of US$ 2,190 Million by 2024, expanding at a CAGR of around 16.5% during 2019-2024.

Browse full report with Table of Contents: https://www.imarcgroup.com/hospital-acquired-disease-testing-market